CLAIMS

1. A vaccine composition comprising an influenza virus peptide comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs: 1 to 21, in which the peptide is attached to a gold glyconanoparticle.

2. A vaccine composition according to Claim 1, in which the influenza virus peptide comprising a CD8+ T cell epitope is attached to the gold glyconanoparticle via a linker.

3. A vaccine composition according to Claim 1 or 2, which comprises two or more influenza virus peptides each comprising a different CD8+ T cell epitope.

4. A vaccine composition according to Claim 3, in which the two or more influenza virus peptides are two or more of the peptides set out in SEQ ID NOs: 1 to 21.

5. A vaccine composition according to any preceding claim, further comprising an influenza virus peptide comprising a CD4+ T cell epitope.

6. A vaccine composition according to Claim 5, in which the influenza virus peptide comprising a CD4+ T cell epitope is attached to a nanoparticle.

7. A vaccine composition according to Claim 6, in which the nanoparticle to which the influenza virus peptide comprising a CD4+ T cell epitope is attached is a gold nanoparticle, a calcium phosphate nanoparticle, or a silicon nanoparticle.

8. A vaccine composition according to Claim 6 or 7, in which the influenza virus peptide comprising a CD4+ T cell epitope is attached to the nanoparticle via a linker.

9. A vaccine composition according to any preceding claim, in which the influenza virus peptide comprising a CD8+ T cell epitope further comprises a CD4+ T cell epitope.

10. A vaccine composition according to Claim 9, in which the influenza virus peptide comprising a CD8+ T cell epitope and a CD4+ T cell epitope comprises one or more of the peptides set out in SEQ ID NOs: 22 to 27.

11. A vaccine composition according to any preceding claim, comprising at least two influenza virus peptides comprising a CD8+ T cell epitope which each interacts with a different HLA supertype.

12. A vaccine composition according to any preceding claim, which comprises at least one immunogenic peptide that interacts with at least two different HLA supertypes.

13. A vaccine composition according to Claim 11 or 12, in which the at least two different HLA supertypes are selected from HLA-A1, HLA-A2, HLA-A3, HLA-A24, HLA-B7, HLA-B8, HLA-B27, HLA-B44, HLA-B58 and HLA-B62.

14. A vaccine composition according to Claim 13, in which the at least two different HLA supertypes are HLA-A2 and HLA-A24.

15. A vaccine composition according to any preceding claim for use in a method of preventing or treating an influenza virus infection in an individual.

16. A vaccine composition according to Claim 15, in which the influenza virus is a pandemic influenza virus.

CLAIMS

1. A vaccine composition comprising an influenza virus peptide comprising one or more of the CD8+ T cell epitopes set out in SEQ ID NOs: 1 to 21, in which the peptide is attached to a gold glyconanoparticle.

2. A vaccine composition according to Claim 1, in which the influenza virus peptide comprising a CD8+ T cell epitope is attached to the gold glyconanoparticle via a linker.

3. A vaccine composition according to Claim 1 or 2, which comprises two or more influenza virus peptides each comprising a different CD8+ T cell epitope.

4. A vaccine composition according to Claim 3, in which the two or more influenza virus peptides are two or more of the peptides set out in SEQ ID NOs: 1 to 21.

5. A vaccine composition according to any preceding claim, further comprising an influenza virus peptide comprising a CD4+ T cell epitope.

6. A vaccine composition according to Claim 5, in which the influenza virus peptide comprising a CD4+ T cell epitope is attached to a nanoparticle, which is (a) a gold glyconanoparticle according to Claim 1 or (b) a further nanoparticle.

7. A vaccine composition according to Claim 6, in which the further nanoparticle to which the influenza virus peptide comprising a CD4+ T cell epitope is attached is a gold nanoparticle, a calcium phosphate nanoparticle, or a silicon nanoparticle.

8. A vaccine composition according to Claim 6 or 7, in which the influenza virus peptide comprising a CD4+ T cell epitope is attached to the nanoparticle via a linker.

9. A vaccine composition according to any preceding claim, in which the influenza virus peptide comprising a CD8+ T cell epitope further comprises a CD4+ T cell epitope.

10. A vaccine composition according to Claim 9, in which the influenza virus peptide comprising a CD8+ T cell epitope and a CD4+ T cell epitope comprises one or more of the peptides set out in SEQ ID NOs: 22 to 27.

11. A vaccine composition according to any preceding claim, comprising at least two influenza virus peptides comprising a CD8+ T cell epitope which each interacts with a different HLA supertype.

12. A vaccine composition according to any preceding claim, which comprises at least one immunogenic peptide that interacts with at least two different HLA supertypes.

13. A vaccine composition according to Claim 11 or 12, in which the at least two different HLA supertypes are selected from HLA-A1, HLA-A2, HLA-A3, HLA-A24, HLA-B7, HLA-B8, HLA-B27, HLA-B44, HLA-B58 and HLA-B62.

14. A vaccine composition according to Claim 13, in which the at least two different HLA supertypes are HLA-A2 and HLA-A24.

15. A vaccine composition according to any preceding claim for use in a method of preventing or treating an influenza A and/or influenza B virus infection in an individual.